Heather Wakelee, MD, discusses the rationale and findings for two combination regimens in EGFR-mutant non-small cell lung cancer, as well as the implications for our understanding of mechanisms of resistance.
Original Article: Targeting Acquired Resistance Leads EGFR+ NSCLC Research Efforts